Home   Add a Resource   Modify a Resource   What's New   What's Cool   Top Rated   Email Updates   Random Link 
Search
 

More search options
 
 
AAAAI - Member Center: Hot Topic: FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma
  June 2003 article on the drug's US approval. Includes information about results of clinical trials.
AAAAI - Member Center: Hot Topic: FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma PreviewTraffic Stats for AAAAI - Member Center: Hot Topic: FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma
Hits to AAAAI - Member Center: Hot Topic: FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma: 0 | Rating: 0 | Votes: 0

Visit AAAAI - Member Center: Hot Topic: FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma | Rate AAAAI - Member Center: Hot Topic: FDA Approves Omalizumab (Xolair), a Recombinant Anti-IgE Antibody, to Treat Allergic Rhinitis and Allergic Asthma

 
   
Pages Updated On: 10-Oct-2005 - 19:18:02
[an error occurred while processing this directive]